Literature DB >> 1976142

The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.

G Oster1, D M Huse, T E Delea, G A Colditz, J M Richter.   

Abstract

In recent years, many new over-the-counter (OTC) medications have resulted from the granting of OTC status by the U.S. Food and Drug Administration to drug entities that previously were available only by prescription (Rx). While the benefits to consumers of Rx-to-OTC switches may be substantial, they also involve some degree of risk, as usage typically expands and physician supervision diminishes. This study explores the potential utility of techniques of decision analysis in evaluating the balance of these benefits and risks. Histamine H2 receptor antagonists (H2-blockers), which are currently available only by prescription, are presented as a case study and were examined to determine how OTC availability of these agents would alter the patterns, effectiveness, and risks of self-treatment for acid-peptic disorders. Currently, about 5.7 million persons experience an episode of dyspepsia during any given quarter, of whom 3.5 million self-medicate with antacids. Study results indicate that OTC availability of H2-blockers would: 1) increase the proportion of persons with dyspepsia who self-medicate from 61.8% currently to 64.1%; 2) increase the proportion of persons who experience complete relief of their symptoms while self-medicating from 37.9% currently to 43.2%; 3) result in 14 additional cases of serious hematologic disorders and an additional 22,000 instances of minor side effects per quarter, but cause the overall rate of side effects among persons who self-medicate to decline; 4) cause an additional 300 persons per quarter with gastric cancer to self-medicate before seeking professional care, but cause no change in the median time between onset of symptoms and the decision to seek such care; and 5) decrease by 277,000 the number of persons per quarter who seek professional care for dyspepsia. On balance, results suggest that OTC H2-blockers may be a relatively safe and effective means of self-care for acid-peptic disorders, and may substantially reduce the number of patient encounters with the medical care system for minor gastrointestinal complaints. This study also illustrates the potential utility of the techniques of decision analysis to the formulation of drug regulatory policy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976142     DOI: 10.1097/00005650-199009000-00012

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  12 in total

1.  The costs and benefits of switching a drug from prescription-only to over-the-counter status: a review of methodological issues and current evidence.

Authors:  F Andersson; E Hatziandreu
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

Review 2.  Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases?

Authors:  S Holt
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 3.  Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Authors:  J E Frampton; D McTavish
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 4.  Formulary management of drugs for cancer-associated hypercalcaemia.

Authors:  S J Gallacher
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

5.  Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.

Authors:  R F Tasch; R Goeree; C J Henke; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

6.  Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

Authors:  R H Hunt
Journal:  CMAJ       Date:  1996-01-01       Impact factor: 8.262

7.  The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.

Authors:  J H Gurwitz; T J McLaughlin; L S Fish
Journal:  Health Serv Res       Date:  1995-12       Impact factor: 3.402

8.  Reflections on a month in the life of the Ontario Drug Benefit Plan.

Authors:  W McIsaac; C D Naylor; G M Anderson; B J O'Brien
Journal:  CMAJ       Date:  1994-02-15       Impact factor: 8.262

9.  Safety implications of the over-the-counter availability of H2-antagonists.

Authors:  M Andersen; J S Schou
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

10.  Are H2 receptor antagonists safe over the counter drugs?

Authors:  M Andersen; J S Schou
Journal:  BMJ       Date:  1994 Aug 20-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.